Pacira BioSciences (PCRX) Change in Account Payables (2010 - 2026)

Pacira BioSciences' Change in Account Payables history runs 12 years deep, the most recent figure standing at -$936000.0 for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 137.99% year-over-year to -$936000.0 in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 171.85% decrease from a year earlier, with the FY2025 full-year figure at -$5.6 million, down 281.52% from the prior year.
• Change in Account Payables climbed to -$936000.0 in Q1 2026 per PCRX's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $9.7 million in Q2 2024 and bottomed at -$12.0 million in Q3 2025.
• The 5-year median for Change in Account Payables is -$325000.0 (2024), against an average of $219882.4.
• Across the five-year window, Change in Account Payables surged 932.94% in 2023 and tumbled 1985.87% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $1.6 million in 2022, then plunged by 167.38% to -$1.1 million in 2023, then jumped by 69.68% to -$325000.0 in 2024, then plunged by 801.23% to -$2.9 million in 2025, then soared by 68.04% to -$936000.0 in 2026.
• Per Business Quant, the three latest PCRX Change in Account Payables figures stand at -$936000.0 (Q1 2026), -$2.9 million (Q4 2025), and -$12.0 million (Q3 2025).